Ziglim-MV 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual and prolonged release of active ingredients, promoting consistent plasma concentrations and improving patient compliance by reducing dosing frequency. Ziglim-MV 1 Tablet SR is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy or dual therapy with these agents is insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. This combination therapy offers a multifaceted approach to glycemic management by targeting different pathophysiological mechanisms of type 2 diabetes.